Evidence map›Paper›PMID 34289083›Full record

ArticleBritish journal of pharmacology2022

Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors.

Michael L Garelja, Rebekah L Bower, Margaret A Brimble, Shanan Chand, Paul W R Harris, Muhammad Aqfan Jamaluddin, Jakeb Petersen, Andrew Siow, Christopher S Walker, Debbie L Hay

Open access · greenAbstract read
In one paragraph

Article in British journal of pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Future targets for migraine treatment beyond CGRP.The journal of headache and pain · 2023
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Calcitonin receptor antibody validation and expression in the rodent brain.Cephalalgia : an international journal of headache · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Michael L GareljaDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0001-5332-1236
Rebekah L BowerSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.
Margaret A BrimbleSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-7086-4096
Shanan ChandSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.
Paul W R HarrisSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.
Muhammad Aqfan JamaluddinSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.
Jakeb PetersenSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.
Andrew SiowSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.
Christopher S WalkerSchool of Biological Sciences, University of Auckland, Auckland, New Zealand.ORCID 0000-0001-8151-4123
Debbie L HayDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-9558-5122
University of Auckland · NZ

Funding

Target validation of a novel CGRP receptor in migraineRF1NS113839 · NINDS · UNIVERSITY OF IOWA · PI HAY, DEBBIE L, RUSSO, ANDREW F · 2019 to 2019
$3.1M
NINDS NIH HHS RF1 NS113839
6 · The paper itself

Abstract

background and purposeThe calcitonin (CT) receptor family is complex, comprising two receptors (the CT receptor [CTR] and the CTR-like receptor [CLR]), three accessory proteins (RAMPs) and multiple endogenous peptides. This family contains several important drug targets, including CGRP, which is targeted by migraine therapeutics. The pharmacology of this receptor family is poorly characterised in species other than rats and humans. To facilitate understanding of translational and preclinical data, we need to know the receptor pharmacology of this family in mice. EXPERIMENTAL APPROACH: Plasmids encoding mouse CLR/CTR and RAMPs were transiently transfected into Cos-7 cells. cAMP production was measured in response to agonists in the absence or presence of antagonists. KEY

resultsWe report the first synthesis and characterisation of mouse adrenomedullin, adrenomedullin 2 and βCGRP and of mouse CTR without or with mouse RAMPs. Receptors containing m-CTR had subtly different pharmacology than human receptors; they were promiscuous in their pharmacology, both with and without RAMPs. Several peptides, including mouse αCGRP and mouse adrenomedullin 2, were potent agonists of the m-CTR:m-RAMP3 complex. Pharmacological profiles of receptors comprising m-CLR:m-RAMPs were generally similar to those of their human counterparts, albeit with reduced specificity. CONCLUSION AND IMPLICATIONS: Mouse receptor pharmacology differed from that in humans, with mouse receptors displaying reduced discrimination between ligands. This creates challenges for interpreting which receptor may underlie an effect in preclinical models and thus translation of findings from mice to humans. It also highlights the need for new ligands to differentiate between these complexes. LINKED ARTICLES: This article is part of a themed issue on Advances in Migraine and Headache Therapy (BJP 75th Anniversary).. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.3/issuetoc.

Indexed as

Migraine DisordersPeptide HormonesAdrenomedullinAnimalsCalcitoninCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinHumansLigandsMiceRatsReceptor Activity-Modifying Protein 1Receptor Activity-Modifying ProteinsReceptors, AdrenomedullinReceptors, CalcitoninAdrenomedullinCalcitoninCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinLigandsPeptide HormonesReceptor Activity-Modifying Protein 1Receptor Activity-Modifying ProteinsReceptors, AdrenomedullinReceptors, Calcitoninadrenomedullinamylincalcitonincalcitonin receptorcalcitonin receptor-like receptorCGRPreceptor activity-modifying protein

Identifiers

PMID34289083
PMCPMC8776895
OpenAlexW3183324177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.